ChemicalBook >> journal list >> Cancer Cell International >>article
Cancer Cell International

Cancer Cell International

IF: 5.3
Download PDF

FPR3 orchestrates macrophage polarization in breast cancer: multi-omics dissection of prognostic relevance and therapeutic targeting

Published:18 August 2025 DOI: 10.1186/s12935-025-03942-4 PMID: 40826412
Ying Chen, Xin Tang, Liran Zhu, Yi Wang, Gaopeng Li, Wulin Yang

Abstract

Background: The N-formyl peptide receptor family (FPRs) is implicated in the progression of diverse cancer types, yet studies specifically exploring their roles in breast cancer remain scarce.

Methods: A comprehensive analysis integrating bulk RNA-seq transcriptomics, methylomics, single-cell transcriptomics, and spatial single-cell transcriptomics data was conducted to elucidate the distinctive characteristics of FPRs in breast cancer. This study particularly focused on delineating the e xpression profiles of FPR3 across distinct breast cancer subtypes, while systematically investigating its prognostic implications and association with macrophage polarization patterns in breast cancer patients. Furthermore, molecular docking analysis was performed to screen potential therapeutic compounds targeting FPR3, providing insights into its druggability.

Results: Notably, FPR3 was found to be highly expressed in macrophages within breast cancer tissues, with a notably elevated level in HER2-positive and triple-negative breast cancer (TNBC) subtypes, both of which are associated with poor prognosis. FPR3 expression inversely correlates with promoter methylation levels. Further analysis of pan-cancer immune infiltration patterns uncovered a striking association between FPR3 and macrophage infiltration, as well as their polarization status. Knockdown of FPR3 expression in macrophages markedly enhanced the expression of IL6, TNF-α, and TGF-β, while significantly reducing IL10 levels, indicative of a shift towards an M1-like macrophage phenotype. Through computational molecular docking analyses, Otamixaban and Rivaroxaban emerged as promising candidate inhibitors of FPR3.

Conclusions: These findings underscore the profound infiltration of FPR3 + macrophages in breast cancer patients with adverse prognoses, highlighting FPR3 as a potential therapeutic target for intervening breast cancer aggressiveness.

Substances (14)

Materials
Procduct Name CAS Molecular Formula Supplier Price
Rivaroxaban 366789-02-8 C19H18ClN3O5S 1014 suppliers $5.00-$1208.70
Rivaroxaban 366789-02-8 C19H18ClN3O5S 1014 suppliers $5.00-$1208.70
Rivaroxaban 366789-02-8 C19H18ClN3O5S 1014 suppliers $5.00-$1208.70
Rivaroxaban 366789-02-8 C19H18ClN3O5S 1014 suppliers $5.00-$1208.70
PHORBOL 12-MYRISTATE 13-ACETATE 16561-29-8 C36H56O8 413 suppliers $37.00-$2757.40
PHORBOL 12-MYRISTATE 13-ACETATE 16561-29-8 C36H56O8 413 suppliers $37.00-$2757.40
PHORBOL 12-MYRISTATE 13-ACETATE 16561-29-8 C36H56O8 413 suppliers $37.00-$2757.40
PHORBOL 12-MYRISTATE 13-ACETATE 16561-29-8 C36H56O8 413 suppliers $37.00-$2757.40
Rivaroxaban 366789-02-8 - Inquiry
Rivaroxaban 366789-02-8 - Inquiry

Similar articles

IF:6.9

Therapeutic effects of guanidine hydrochloride on breast cancer through targeting KCNG1 gene.

Biomedicine & Pharmacotherapy Mehdi Roshanian Bakhsh, Leila Rouhi,etc Published: 1 August 2023
IF:7.1

Cold atmospheric plasma restores skewed macrophage polarization in triple negative breast cancers via enhancing KAT6A acetylation

Free Radical Biology and Medicine Kaiyuan Zhu, Qing lv,etc Published: 23 November 2024
IF:4.6

Targeting cuproptosis by zinc pyrithione in triple-negative breast cancer.

iScience Xu Yang, Li Deng,etc Published: 16 October 2023